Results 201 to 210 of about 45,567 (253)

Therapeutic Innovations for Monkeypox Inhibition. [PDF]

Int J Mol Sci
De N, Bhadra J, Momin MSA, Mitra K, Bhunia D, Sannigrahi A.   +5 more
europepmc   +1 more source

Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates. [PDF]

Mol Ther Nucleic Acids
Pradeep SP, Ruchi R, Bahal R.
europepmc   +1 more source

Targeting Non-Coding RNAs as a Potential Therapeutic and Delivery Strategy Against Neurodegenerative Diseases. [PDF]

Int J Mol Sci
Bougea A.
europepmc   +1 more source

RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review. [PDF]

Pharmaceutics
Generalov E, Shevelev A, Romanov D, Tarasova O, Pozdniakova N.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The delivery of antisense therapeutics

Advanced Drug Delivery Reviews, 2000
Antisense oligonucleotides, ribozymes and DNAzymes have emerged as novel, highly selective inhibitors or modulators of gene expression. Indeed, their use in the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. The first antisense drug molecule is now available for clinical use in Europe and
Saghir Akhtar
exaly   +3 more sources

Cellular delivery of antisense oligonucleotides

European Journal of Pharmaceutics and Biopharmaceutics, 2000
Antisense oligonucleotides can be successfully employed to inhibit specifically gene expression. However, many oligonucleotide classes are polyanions and cannot passively transit the cell membrane. Thus, the use of naked oligonucleotides for antisense purposes poses some rather stringent challenges, and it is not a trivial task to appropriately ...
Irina Lebedeva, L Benimetskaya, C A Stein   +2 more
exaly   +3 more sources

The cellular delivery of antisense oligonucleotides and ribozymes

Drug Discovery Today, 2001
The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu.
Saghir Akhtar
exaly   +3 more sources

Transdermal delivery of antisense compounds

Advanced Drug Delivery Reviews, 2000
Antisense technology holds tremendous promise for therapeutic applications and the study of gene function. A broadly applicable route of administration that would provide for non-invasive, simple, and convenient delivery is highly desirable. Application of oligonucleotides to the skin may represent a solution to the delivery question for both local ...
Patrick Iversen, R M Brand
exaly   +3 more sources

Novel non-endocytic delivery of antisense oligonucleotides

Advanced Drug Delivery Reviews, 2000
Antisense oligonucleotides (ONs) have several properties that make them attractive as therapeutic agents. Hybridization of antisense ONs to their complementary nucleic acid sequences by Watson-Crick base pairing is a highly selective and efficient process.
Yon Rojanasakul
exaly   +3 more sources